XDx Announces Plenary Session Presentation of IMAGE Trial Results at International Society for Heart & Lung Transplantation 30th Anniversary Meeting
BRISBANE, Calif., April 16 /PRNewswire/ — XDx, Inc., a molecular diagnostics company focused on noninvasive tests for the monitoring of immune-mediated conditions, today announced that results from its Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial will be presented by Dr. Michael X. Pham, Stanford University Medical Center, during a plenary session at the International Society for Heart & Lung Transplantation 30th Anniversary Meeting & Scientific Sessions in Chicago this month.
IMAGE is a multicenter, randomized clinical trial of 602 heart transplant patients comparing XDx’s AlloMapÃ‚® Molecular Expression Testing, a noninvasive rejection surveillance method utilizing gene expression profiling testing, to routine endomyocardial biopsy surveillance to monitor acute cellular rejection in cardiac transplant recipients. This comparative effectiveness research study was designed to demonstrate the non-inferiority of clinical outcomes of heart transplant recipients managed with the AlloMap test compared with conventional endomyocardial biopsy.
Presentation Details Comparison of Gene Expression Profiling and Endomyocardial Biopsy for Surveillance of Acute Cardiac Cellular Rejection: Results from the IMAGE Trial (Abstract #98) Session: Plenary Session Date: Thursday, April 22, 2010, 8:45 a.m. CDT Location: Hilton Chicago, International Ballroom
Following the plenary session, XDx is sponsoring a satellite symposium entitled: “The Future of Rejection Surveillance after Cardiac Transplantation” at 12:30 p.m. CDT in which heart transplant cardiologists will further discuss implications of the IMAGE findings. The symposium will take place in the Hilton Chicago, International Ballroom.
About AlloMapÃ‚® Molecular Expression Technology
AlloMap Molecular Expression Testing is a gene expression test that uses a simple, noninvasive method of blood sample collection and can be used to reliably indicate the low probability of acute cellular rejection in stable heart transplant recipients. AlloMap testing measures the expression levels of 20 specific genes in the blood. The combined expression of these genes, represented as an AlloMap test score, can help a physician evaluate whether a patient is at low risk for rejection when used together with standard clinical assessment. AlloMap, performed in the XDx CLIA certified laboratory, has been commercially available since 2005 and was cleared by the U.S. Food and Drug Administration in 2008.
XDx, based in Brisbane, Calif., is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary test, AlloMapÃ‚® Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management.
Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx’s noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit www.xdx.com.
SOURCE XDx, Inc.